Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 22 of 22 entries
View as:

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT03121339 Org: User:
Start: 03/31/17 End: 04/03/18 Due: 04/03/19

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02547792 Org: User:
Start: 10/20/15 End: 11/21/16 Due: 11/21/17

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Phase: N/A Priority: Normal
NCT ID: NCT02830932 Org: User:
Start: 06/22/16 End: 09/20/17 Due: 09/20/18

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04563702 Org: User:
Start: 09/21/20 End: 10/10/21 Due: 10/10/22

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02724254 Org: User:
Start: 01/31/16 End: 07/31/18 Due: 07/31/19

Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

Phase: N/A Priority: Normal
NCT ID: NCT01688297 Org: User:
Start: 09/30/12 End: 04/30/15 Due: 04/30/16

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Phase: N/A Priority: Normal
NCT ID: NCT06672055 Org: User:
Start: 10/08/24 End: 11/30/26 Due: 11/30/27

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT06944717 Org: User:
Start: 03/03/25 End: 05/01/26 Due: 05/01/27

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT02868073 Org: User:
Start: 07/29/16 End: 10/01/17 Due: 10/01/18

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT02918006 Org: User:
Start: 08/31/16 End: 01/19/18 Due: 01/19/19

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

Phase: N/A Priority: Normal
NCT ID: NCT01698060 Org: User:
Start: 09/30/12 End: 11/30/13 Due: 11/30/14

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT05067933 Org: User:
Start: 10/22/21 End: 05/09/23 Due: 05/09/24

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT04875676 Org: User:
Start: 04/30/21 End: 02/16/22 Due: 02/16/23

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

Phase: N/A Priority: Normal
NCT ID: NCT01761123 Org: User:
Start: 01/31/13 End: 10/31/14 Due: 10/31/15

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT03897309 Org: User:
Start: 03/20/19 End: 04/01/21 Due: 04/01/22

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT04854746 Org: User:
Start: 04/26/21 End: 01/04/22 Due: 01/04/23

A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

Phase: N/A Priority: Normal
NCT ID: NCT03024177 Org: User:
Start: - End: - Due: -

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03125473 Org: User:
Start: 04/07/17 End: 05/06/18 Due: 05/06/19

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05626803 Org: User:
Start: 01/26/23 End: 10/16/23 Due: 10/16/24

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05213728 Org: User:
Start: 01/24/22 End: 02/24/22 Due: 02/24/23

Norovirus Challenge Study

Phase: N/A Priority: Normal
NCT ID: NCT05212168 Org: User:
Start: 12/27/21 End: 10/27/23 Due: 10/27/24

Safety Study of an Oral Vaccine to Prevent Avian Influenza

Phase: N/A Priority: Normal
NCT ID: NCT01335347 Org: User:
Start: 04/30/11 End: 09/30/12 Due: 09/30/13